This page shows what was measured, who it was measured in, and what that does not settle.
What Tezepelumab does in the body
8 pM and blocks its interaction with the heterodimeric TSLP receptor.
From the FDA-approved label: Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2λ that binds to human TSLP with a dissociation constant of 15. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in inflammatory cascades. Airway and mucosal inflammation are important components of the pathogenesis of asthma and CRSwNP. , histamine, eicosanoids, leukotrienes, cytokines) are involved in airway and mucosal inflammation.
Why people take it. TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. It is a prescription or clinician-administered medicine where it is approved.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · RJ1IW3B4QX · read 2026-08-29
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 122 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma
✗ The study did not show it
Who was studied
NCT03347279
How many people
1061
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Annualised rate of moderate or severe COPD exacerbations
✗ The study did not show it
Who was studied
NCT06883305
How many people
990
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Annualised rate of moderate or severe COPD exacerbations
✗ The study did not show it
Who was studied
NCT06878261
How many people
990
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Exposure Adjusted Incidence Rates of AEs/SAEs
✗ The study did not show it
Who was studied
NCT03706079
How many people
951
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Primary endpoint ：
✗ The study did not show it
Who was studied
NCT07302516
How many people
636
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Annualized Asthma Exacerbation Rate (AER) Through Week 52
✗ The study did not show it
Who was studied
NCT02054130
How many people
584
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
□Living longer, or avoiding a major eventNo evidence recorded. Death, a heart attack, a stroke, a hospital stay.No registered study measures this.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.1 registered measure of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.2 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
□Cells in a dishNo evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
total nasal symptom
Measured
Things only a test, a scale or a device shows.
maximum observed serum concentration
maximum observed concentration
Meaningful
Things that change how a life goes, not only a number.
No registered study measured anything of this kind.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (31)
adverse events
treatment emergent adverse events
dose normalized auc
dose normalized cmax
time to reach cmax
terminal phase elimination half life
apparent clearance
investigator s global assessment of 0 or 1 at week 16
annual asthma exacerbation rate
auc0 inf
auc0 t
cmax
tmax
t1/2
cl/f
vz/f
urticaria activity over 7 days at week 16
annualized asthma exacerbation rate
annualized severe asthma exacerbation rate
status of asthma control
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 26 days
Read from the label, which states: “The elimination half-life was approximately 26 days.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. ( 1.1 ) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of TEZSPIRE have not been established in patients younger than 12 years of age with asthma.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
On older people, the label states: “Asthma Of the 665 patients with asthma treated with TEZSPIRE in clinical trials (PATHWAY and NAVIGATOR) for severe asthma, 119 patients (18%) were 65 years or older.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of tezepelumab-ekko in human milk, its effects on the breastfed infant, or its effects on milk production.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Still being tested
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. It is a prescription or clinician-administered medicine where it is approved.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
The identity record classes it as Monoclonal Antibody (mAb).
No source is stored against this line.
What is in the pack
Sold as injection, solution, given by the subcutaneous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Tezepelumab appears in spontaneous reports to regulators. Across the 1 most-reported reaction terms, 5 reaction mentions were counted. One report can name several reactions.
The recorded terms (1)
asthma — 5 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
2 products list this as an active ingredient in the United States drug directory. 2 of them contain it and nothing else.
FDA National Drug Code directory · 55513-112 · read 2026-08-29
They are sold as injection, solution, taken subcutaneous.
FDA National Drug Code directory · 55513-112 · read 2026-08-29
The regulator's established pharmacologic class for it is thymic stromal lymphopoietin blocker [epc] and thymic stromal lymphopoietin blockers [moa].
FDA National Drug Code directory · 55513-112 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-29
TEZSPIRE is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: a clear to opalescent, colorless to light yellow solution available as: • 210 mg/1.91 mL (110 mg/mL) solution in a single-dose glass vial. • 210 mg/1.91 mL (110 mg/mL) solution in…, recorded as fda label in effect 2025-10-17 in the United States.
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Tezepelumab studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Tezepelumab are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
RJ1IW3B4QX
CAS registry number
1572943-04-4
ChEMBL
CHEMBL2109594
WHO international nonproprietary name list entry
10172
RxNorm concept
2587789
EMA substance identifier
100000165774
DrugBank
DB15090
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
The identity record classes it as Monoclonal Antibody (mAb).
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
The earliest marketing start date recorded for a listed product is 20211217.
FDA National Drug Code directory · 55513-112 · read 2026-08-29
What is missing or unclear◇Read from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q1
What did Tezepelumab's largest trial (16640 people) and its longest (19 years) measure?
16640 people in Tezepelumab's largest registered study, 19 years in its longest registered window, measuring Area Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity]). ClinicalTrials.gov · 2026-09-01
22 phase3, 14 phase2, 10 phase1, 6 na or unstated, 3 na, 2 phase4; NCT06456450; 2043-02-28; no ageing endpoint recorded. Last human test completed 2026, NCT05651841.
Interpretation These counts include studies where Tezepelumab was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase3
22
phase2
14
phase1
10
na or unstated
6
na
3
phase4
2
1 more recorded row
Last recorded human testNCT05651841
2026-06-23
recorded 2026-09-01 · last checked 2026-09-04
Q2
Tezepelumab was tested only in human — what did it show?
"Tezepelumab as a monotherapy in atopic dermatitis did not reach the targeted efficacy level pre-established for this patient population."; 2 of 56 registered studies
Show the evidence
Trial
NCT03809663
terminated; "Tezepelumab as a monotherapy in atopic dermatitis did not reach the targeted efficacy level pre-established for this patient population."
NCT05398263
terminated; "The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral corticosteroids for severe asthma treatment. The termination decision was not related to safety…"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Tezepelumab used MEDI9929 70 mg — over how long?
4 recorded entries; human; also "MEDI9929 210 mg", "MEDI9929 280 mg", "MEDI9929, 140 mg"
Show the evidence
human
NCT02054130
MEDI9929 70 mg
NCT02054130
MEDI9929 210 mg
NCT02054130
MEDI9929 280 mg
NCT02512900
MEDI9929, 140 mg
recorded 2026-09-01 · last checked 2026-09-04
Q5
Tezepelumab's half-life is 26 days — which schedules were studied?
26 days, the half-life Tezepelumab's label states. openfda-label · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · 2026-08-30
bioavailability 77% %.
Show the evidence
half life
26 days; The elimination half-life was approximately 26 days.
bioavailability
77% %; Based on population pharmacokinetic analysis, the estimated absolute bioavailability was approximately 77%.
metabolism
Metabolism Tezepelumab-ekko is a human monoclonal antibody (IgG2λ) that is degraded by proteolytic enzymes widely distributed in the body and not metabolized by hepatic enzymes.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Could one person measure Tezepelumab's effect on adverse events?
Adverse events: measured in Tezepelumab's trials.
Interpretation adverse events is the recorded endpoint.
Show the evidence
biomarkers
adverse events; 2026-09-01
treatment emergent adverse events; 2026-09-01
dose normalized auc; 2026-09-01
maximum observed serum concentration; 2026-09-01
dose normalized cmax; 2026-09-01
time to reach cmax; 2026-09-01
14 more recorded rows
biomarkers
terminal phase elimination half life; 2026-09-01
biomarkers
apparent clearance; 2026-09-01
biomarkers
investigator s global assessment of 0 or 1 at week 16; 2026-09-01
biomarkers
annual asthma exacerbation rate; 2026-09-01
biomarkers
maximum observed concentration; 2026-09-01
biomarkers
auc0 inf; 2026-09-01
biomarkers
auc0 t; 2026-09-01
biomarkers
cmax; 2026-09-01
biomarkers
tmax; 2026-09-01
biomarkers
t1/2; 2026-09-01
biomarkers
cl/f; 2026-09-01
biomarkers
vz/f; 2026-09-01
biomarkers
urticaria activity over 7 days at week 16; 2026-09-01
biomarkers
annualized asthma exacerbation rate; 2026-09-01
half life
2026-09-04; halfLife; 26 days; 2026-08-30
human trials at or under30
7
smallest human trial
10; NCT06740045; PHASE3; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; NOT_YET_RECRUITING
Q7
Which of adverse events, annual asthma exacerbation rate and annualized asthma exacerbation rate did Tezepelumab's trials measure?
adverse events, annual asthma exacerbation rate and annualized asthma exacerbation rate lead 34 outcome terms across Tezepelumab's trials. ClinicalTrials.gov · 2026-09-01
maximum observed serum concentration, dose normalized cmax, time to reach cmax, terminal phase elimination half life, apparent clearance and investigator s global assessment of 0 or 1 at week 16 follow.
Show the evidence
adverse events
1
treatment emergent adverse events
1
dose normalized auc
1
maximum observed serum concentration
1
dose normalized cmax
1
time to reach cmax
1
14 more recorded rows
terminal phase elimination half life
1
apparent clearance
1
investigator s global assessment of 0 or 1 at week 16
1
annual asthma exacerbation rate
1
maximum observed concentration
1
auc0 inf
1
auc0 t
1
cmax
1
tmax
1
t1/2
1
cl/f
1
vz/f
1
urticaria activity over 7 days at week 16
1
annualized asthma exacerbation rate
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Tezepelumab's 25 ongoing trials reports first?
Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels; Annualized severe asthma exacerbation rate (AAER); latest 2043-02-28
Show the evidence
Trial
NCT05583227
"Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis"; n 368; "Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels"; 2027-03-23
NCT06023589
"A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma"; n 231; "Annualized severe asthma exacerbation rate (AAER)"; 2030-08-23
NCT06189742
"Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)"; n 19; "Total Nasal Symptom Score (TNSS)"; 2026-12
NCT06230354
"Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis"; n 42; "Proportion of participants who are in remission at week 24"; 2026-09
NCT06438913
"Tezepelumab Treatment in Korean Severe Asthma Patients"; n 100; "Effects of Tezepeluma on Cough"; 2026-12-31
NCT06456450
"Taiwan Severe Asthma Biologic Registry"; n 500; "Status of Asthma Control"; 2043-02-28
14 further recorded trials
NCT06473779
"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma."; n 326; "Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase."; 2027-06-25
NCT06705764
"Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)"; n 100; "Proportion of patients who have moderate and severe exacerbations of asthma"; 2026-11
NCT06706817
"A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab"; n 181; "Change from baseline in nasal congestion"; 2027-01-13
NCT06740045
"Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma"; n 10; "Eosinophil Count"; 2025-06
NCT06878261
"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)"; n 990; "Annualised rate of moderate or severe COPD exacerbations"; 2029-06-05
NCT06883305
"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)"; n 990; "Annualised rate of moderate or severe COPD exacerbations"; 2029-06-05
NCT06948396
"Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy"; n 315; "Demographic and Clinic characterization"; 2027-05-30
NCT06951867
"Tezspire Cardiac Events PASS"; n 16640; "composite outcome MACE"; 2029-05-31
NCT07013123
"Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab"; n 38; "Annualized total number of asthma exacerbations under acarizax/placebo treatment"; 2029-08-18
NCT07015996
"Efficacy of Tezepelumab in Peanut Oral Immunotherapy"; n 62; "Consumption of a cumulative dose of 4000 mg of peanut protein without dose-limiting symptoms during the open Oral Food Challenge (OFC)"; 2028-09-16
NCT07046117
"Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps"; n 20; "Change in cell index"; 2028-08-01
NCT07302516
"Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma"; n 636; "Primary endpoint ："; 2029-12
NCT07327697
"A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects"; n 178; "Pharmacokinetics Endpoint"; 2026-09
NCT07363642
"Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab"; n 400; "To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma control"; 2029-03-31
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 4 trials of Tezepelumab posted no result?
Posted no result
4 of 4 completed trials
Registrations
NCT01913028, NCT02698501, NCT03989544 and NCT04362410
Completion dates
oldest 2014-01; newest 2020-10-09
Show the evidence
Trial
NCT01913028
2014-01
NCT02698501
2019-10-07
NCT03989544
2019-12-30
NCT04362410
2020-10-09
Q10
At the median, Tezepelumab's trials enrolled 123 people — anything larger?
Median enrolment
123
Largest enrolment
16640
Registered trials counted
56
Q11
What do 5 spontaneous reports say about Tezepelumab — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Tezepelumab appears in spontaneous reports to regulators. Across the 1 most-reported reaction term, 5 reaction mentions were counted: asthma 5. open-targets-adr · CHEMBL3707229 · 2026-06-24
Show the evidence
asthma
5
recorded 2026-06-24 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 7 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.